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Abstract 
 
LXRα activation in macrophages enhances regression of atherosclerotic plaques in mice 
by regulating genes crucial for cholesterol efflux, cell motility and inflammation.  
Diabetes, however, impairs plaque regression in mice.  LXRα is phosphorylated at serine 
198 (pS198), which affects the expression of genes controlling inflammation, lipid 
metabolism and cell movement.  We hypothesize that LXRα function is affected by 
hyperglycemia through changes in LXRα pS198.  Indeed, macrophages cultured in 
diabetes relevant high glucose versus normal glucose display alterations in LXR-
dependent gene expression and increased LXRα pS198.  We therefore examined the 
consequence of disrupting LXRα phosphorylation (S196A in mouse LXRα) during 
regression of atherosclerosis in normal and diabetic mice.  We find that phosphorylation 
deficient LXRα S196A reduces macrophage retention in plaques in diabetes, which is 
predicted to be anti-atherogenic and enhance plaque regression.  However, this favorable 
effect on regression is masked by increased monocyte infiltration in the plaque attributed 
to leukocytosis in LXRα S196A mice.  RNA-seq of plaque macrophages from diabetic 
S196A mice shows increased expression of chemotaxis and decreased expression of cell 
adhesion genes, consistent with reduced macrophage retention by LXRα S196A.  Thus, 
the non-phosphorylated form of LXRα precludes macrophage retention in the plaque.  
Our study provides the first evidence for a physiological role of LXRα phosphorylation in 
modulating atherosclerosis regression.  Compounds that prevent LXRα phosphorylation 
or ligands that induce the conformation of non-phosphorylated LXRα may selectively 
enhance macrophage emigration from atherosclerotic plaques.   
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INTRODUCTION 
 
Atherosclerosis is an inflammatory disease characterized by lipid-rich plaques in 
the subendothelial space of arterial walls that contain cholesterol-loaded macrophage 
foam cells (1).  If left untreated, a plaque can rupture leading to myocardial infarction or 
stroke.  A major risk factor for atherosclerosis is diabetes (2), the incidence of which 
continues to rise (3).  
Normalization of cholesterol levels has been shown to promote macrophage 
egress and the regression of atherosclerotic plaques in some mouse models [reviewed in 
(4)].  Mice deficient in Liver X Receptors (LXRs) displayed impaired regression through 
a defect in the emigration of plaque macrophages after hypercholesterolemia was 
reversed (5).  LXRs, LXRα and LXRβ, belong to the nuclear receptor superfamily of 
DNA-binding transcription factors and are activated by binding oxysterol cholesterol 
metabolites and cholesterol precursors, and synthetic agonists (6-10).  Increased 
intracellular cholesterol levels in macrophages activate LXRs, which induces expression 
of several genes important in cholesterol efflux and reverse cholesterol transport.  
Previously our lab showed that human LXRα is phosphorylated at serine 198 (which 
corresponds to serine 196 in mouse LXRα) by Casein kinase 2 (CK2) in cultured 
macrophages (11).  This modification has been shown to selectively regulate LXR target 
gene expression, suggesting that it might impact LXR signaling in macrophages in the 
atherosclerotic plaque (12).  In mice, increased LXRα phosphorylation at S196 (hereafter 
LXRα pS196 in mouse and LXRα pS198 in human) in plaque macrophages is associated 
with atherosclerosis progression whereas reduced LXRα pS196 is associated with 
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regression (12).  However, the causal contribution of LXRα phosphorylation in 
atherosclerosis in vivo has not been examined.  
Plaque regression upon reductions in LDL cholesterol levels is significantly 
impaired in diabetic vs. non-diabetic mice (13).  This is consistent with clinical data 
showing that diabetes significantly hampers the regression of human atherosclerosis, 
despite the equivalent drop in lipid levels (14).  Regression in diabetic mice is associated 
with defective reduction of plaque CD68+ cells, suggesting increased macrophage 
retention or increased entry of monocytes despite lipid lowering (13, 15).  In a recent 
study we found that chronic high glucose significantly compromised LXR-dependent 
gene activation relative to normoglycemia in cultured bone marrow derived macrophages 
(16). Because of increased phosphorylation of LXRα at S196 in progressing plaques (12), 
we hypothesized that LXR function is impaired in diabetic mice through the same 
modification and contributes to the impaired regression.   
In this report, we test this hypothesis by interrogating the impact of high glucose 
concentrations on LXRα pS196 in macrophages.  In addition, to better understand the 
biological function of LXRα phosphorylation, we generated a mouse in which the serine 
196 codon has been changed to alanine (S196A), to test the physiological relevance of 
LXRα pS196 in the regression of atherosclerosis in normoglycemic and diabetic settings.  
Remarkably, the genetic prevention of LXRα phosphorylation reduces macrophage 
retention in plaques during regression of atherosclerosis in diabetes.  Underlying this 
reduction in macrophage retention are changes in gene expression by the non-
phosphorylated LXRα that promote chemotaxis and reduce cell adhesion that contribute 
to this important anti-atherogenic phenotype.  
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RESULTS 
Hyperglycemia influences LXR-dependent gene expression and enhances LXRα 
phosphorylation in macrophages  
Atherosclerosis regression upon lipid lowering is hampered in hyperglycemic 
mice (13, 17).  Given the importance of LXRs in atherosclerosis regression (5), we 
hypothesized that hyperglycemia influences receptor function.  Thus, we performed gene 
expression-profiling on RAW 264.7 murine macrophages stably expressing human 
LXRa cultured in diabetes-relevant high glucose (25 mM D-glucose) or normal glucose 
(5.5 mM D-glucose, supplemented with inactive L-glucose to control for osmolality) with 
and without LXR agonists (Supplemental Figure 1A).  This allowed us compare the 
impact of glucose on the transcriptional response of macrophages to LXR activation.  
High compared to normal glucose significantly modulated 1,297 genes; 647 genes 
exhibited enhanced and 650 displayed reduced expression (>1.5 fold; p-value <0.05).  
Interestingly, of the 128 genes that were induced upon ligand treatment, 48% of genes 
(61 out of 128) were modulated by glucose: 31 genes were further induced, whereas 30 
genes had reduced ligand-dependent induction in high compared to normal glucose.  On 
the other hand, of the 48 genes that were repressed by high glucose, 42% of genes (20 out 
of 48) were sensitive to the increase in glucose concentration: 11 genes were further 
repressed whereas 9 genes had less repression with ligand in high compared to normal 
glucose (Figure 1A).  This supported our hypothesis that glucose has a significant effect 
on LXR-dependent gene expression.  Importantly, the gene expression changes affected 
by high glucose were linked to molecular and cellular functions in macrophages 
including cell death and survival, cell movement, cell growth and lipid metabolism 
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(Figure 1B).  High glucose also appeared to control inflammatory signaling, 
atherosclerosis signaling as well as LXR activation pathways (Supplemental Figure 1B).  
Thus, glucose-regulated changes in LXR-dependent gene expression in macrophages 
affects key determinants of atherosclerosis. 
We next sought to interrogate how hyperglycemia influences LXR signaling. 
LXRα phosphorylation at S198 is known to modulate its transcriptional activity at a 
subset of target genes, and promotes pro-inflammatory gene expression while 
suppressing anti-inflammatory gene expression in macrophages (11).  We therefore 
explored the possbility that high glucose affected LXRα function through changes in 
LXRα phosphorylaiton.  RAW 264.7 cells stably expressing human LXRα cultured either 
under normal or diabetes relevant high glucose were examined for effects on LXRα S198 
phosphorylation.  Cells were treated with DMSO as the vehicle control, T0901317, 9-
cisRA or T0901317 and 9-cisRA.  This combination of ligands reduces LXRα pS198 
induced by T0901317 (11).  Consistent with our hypothesis, LXRα pS198 is greatly 
increased under high compared to normal glucose under basal and ligand-treated 
conditions, suggesting a glucose-dependent regulation of LXR phosphorylation (Figure 
1C). 
 
Expression of phosphorylation deficient LXRα S196A in mice does not change 
plasma lipid and glucose levels   
Next we determined whether LXRα phosphorylation affected macrophage 
function during atherosclerosis regression in diabetes.  To do this, we used an inducible 
LXRα S196A phosphorylation deficient knock-in mouse (Supplemental Figure 2).  We 
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employed this strategy so plaques could develop normally under conditions of LXRα WT 
and then be switched to LXRα S196A to isolate the effect of LXR phosphorylation on 
regression (see Figure 2A for study protocol).  Mice homozygous for LXRα S196A 
floxed allele (S196AFL/FL) (18) with or without a tamoxifen inducible CRE recombinase 
(RosaCreERT2;CRE+ or CRE-) were used as donors for bone marrow (BM) 
transplantation into recipient Reversa mice (19).  This is an Ldlr−/− model where the 
hyperlipidemia can be reversed after conditional inactivation of microsomal triglyceride 
transfer protein (Mttp) by pIpC treatment (Figure 2A).  Reversa mice were fed a western 
diet for 16 weeks to allow plaques to develop.  
Mice were separated into six groups: two groups of baseline mice (LXRα 
S196AFL/FL CRE- and LXRα S196AFL/FL CRE+), and four regression groups; 1) LXRα 
WT (S196AFL/FL CRE-) and normoglycemia, 2) LXRα S196A (S196AFL/FL CRE+) and 
normoglycemia; 3) LXRα WT (S196AFL/FL CRE-) and diabetic; 4) LXRα S196A 
(S196AFL/FL CRE+) and diabetic.  Tamoxifen was administered at week 14.5 to all groups 
and this induced recombination of loxP sites in the CRE expressing mice resulting in the 
replacement of the LXRα WT with the LXRα S196A allele.  The regression/diabetic 
mice were administered an intraperitoneal injection of Streptozotocin (STZ) for 5 days 
preceding pIpC treatment so that they became hyperglycemic.  
The reconstitution of bone marrow after transplantation in Reversa mice was 
efficient: 90% of the circulating monocytes were derived from the newly transplanted 
bone marrow (Supplemental Figure 3).  The CRE-mediated recombination at the S196A 
allele upon tamoxifen treatment was also effective.  Notably, the atherosclerotic plaques 
in the aortic roots of mice expressing LXRα S196A (S196AFL/FL CRE+ BM recipients) 
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versus those that express LXRα WT (S196AFL/FL CRE- BM recipients) showed markedly 
reduced LXRα pS196 staining in plaques, without changes in total LXRα abundance 
(Supplemental Figure 4 and 5).  This is indicative of an efficient switch to LXRα S196A 
protein in the plaque.  
The LXRα S196A (S196AFL/FL CRE+) BM recipients had similar glucose levels 
and lipid profiles (cholesterol, triglycerides and HDL cholesterol) compared to their 
LXRα WT (S196AFL/FL CRE-) BM recipient counterparts, suggesting that LXRα S196A 
expression during the 5 weeks of regression did not affect these parameters (Figure 2B 
and 2C and Supplemental Figure 6A and 6B).  As expected, the glucose levels were 
dramatically higher in STZ-treated mice than in control mice (Figure 2B).  Similar 
reductions in cholesterol and triglyceride levels were observed in normal and diabetic 
mice upon reversal of hyperlipidemia (Figure 2C and Supplemental Figure 6A). 
 
Expression of LXRα S196A increases plaque macrophage content in normoglycemic 
but not diabetic mice 
To determine the effect of LXRα S196A on atherosclerosis regression, we 
measured plaque area and their total macrophage content by quantifying the percent of 
the macrophage marker CD68 stained area.  Both groups of baseline mice had similar 
macrophage contents in their plaques since the plaques developed largely under LXRα 
WT conditions (Figure 2D).  After 5 weeks of reduction in plasma cholesterol levels, we 
observed reduced macrophage content in the normoglycemic mice expressing LXRα WT 
indicative of atherosclerosis regression.  However, in mice expressing LXRα S196A 
regression was impaired as evidenced by significantly less reduction in CD68 positive 
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cell content compared to LXRα WT groups under normoglycemic conditions (Figure 
2D).  Consistent with previous findings, diabetic mice with LXRα WT also showed 
impaired plaque regression (13, 15).  Interestingly, unlike the normoglycemic setting, 
LXRα S196A expression did not alter plaque macrophage content under diabetic 
conditions: regression was similarly impaired in diabetic mice expressing LXRα WT and 
LXRα S196A.  As shown before, the total plaque area in aortic roots of the baseline and 
regression groups as well as normoglycemic and diabetic groups remained unchanged 
(Supplemental Figure 7) (13, 15).  Collagen content in the plaques among all the 
regression groups was also unchanged (not shown).  Thus, LXRα S196A expression 
increased plaque macrophage burden and impaired regression in normoglycemic mice but 
did not affect plaque regression in diabetic mice.  
 
LXRα pS196 and diabetes affect apoptosis, necrotic area, and efferocytosis 
In advanced lesions, macrophages undergo apoptosis, and this can affect 
macrophage content within a plaque (24).  Therefore, we measured apoptosis in the 
plaques by staining for cleaved caspase 3.  We found increased apoptosis in LXRα 
S196A plaques under normoglycemic conditions compared to LXRα WT (Figure 3A). 
Relative to WT normoglycemia, diabetes also increased apoptosis in the plaque of LXRα 
WT expressing mice, which was not further increased by LXRα S196A.  
When the apoptotic cells are not efficiently cleared by macrophages in a process 
called efferocytosis, they promote the formation and expansion of a necrotic core that 
creates plaques vulnerable to rupture and thrombosis (3).  We measured necrotic area by 
quantifying the acellular areas within the plaques (15), and found that plaques from 
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LXRα S196A-expressing mice contained significantly larger necrotic areas compared to 
LXRα WT mice under normoglycemia (Figure 3B).  Diabetes also significantly increased 
necrotic areas in wild type mice consistent with previous reports (2), whereas LXRα 
S196A did not further exacerbate plaque necrosis in diabetic mice.   
Since regressing plaques in some groups of mice were associated with 
significantly higher necrotic areas compared to others, this suggested inadequate or 
defective clearance of dying or dead cells by efferocytosis.  To test whether 
hyperglycemia and/or phosphorylation of LXRα at S196 affected efferocytosis, we 
assayed the ability of peritoneal macrophages expressing LXRα WT and LXRα S196A 
cultured in normal and high glucose to efferocytose labeled apoptotic Jurkat cells.  The 
uptake of apoptotic cells (% efferocytosis) was significantly reduced by culturing cells in 
high glucose, and independent of LXRα S196 phosphorylation (Figure 3C).  This would 
help to explain the larger necrotic core in the diabetic atherosclerotic plaques. 
Since LXRα S196 phosphorylation in macrophages had no effect on efferocytosis, 
this suggested that higher plaque necrotic area in mice expressing LXRα S196A 
compared to LXRα WT under normoglycemic condition was due to other factors, such as 
increased apoptosis.  We therefore examined the propensity of peritoneal macrophages 
expressing LXRα WT and LXRα S196A to undergo apoptosis induced by LPS and 
cyclohexamide under normal glucose and high glucose conditions.  Similar levels of 
apoptosis were observed in LXRα WT and LXRα S196A-expressing cells under 
hyperglycemic and normoglycemic conditions (Figure 3D).  Therefore, differences in the 
content of apoptotic cells in the plaque were likely not due to cell intrinsic changes in 
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apoptotic activity of macrophages between LXRα WT and LXRα S196A, but rather, the 
increased macrophage accumulation in the plaque.  
Loss of LXRα S196 phosphorylation increased monocyte recruitment and reversed 
diabetes-associated increased macrophage retention 
We next investigated whether there were alterations in monocyte/macrophage 
trafficking in the plaque that could be responsible for differences in macrophage content 
among the regression groups, using methods we have previously used for this purpose 
(15, 20).  To measure monocyte recruitment, mice were injected with fluorescent latex 
beads 24 hours before harvesting the aortic roots, and the number of beads in the plaque 
was quantified (Figure 4A).  Monocyte labeling was not affected by either diabetes or 
LXRα S196A expression suggesting that the phagocytic ability of circulating monocytes 
was similar in all groups (Supplementary Figure 8A).  Diabetes increased monocyte 
recruitment in mice expressing LXRα WT (Figure 4B), consistent with previous studies 
(15).  Interestingly, mice expressing LXRα S196A also displayed significantly increased 
monocyte recruitment under both normoglycemic and diabetic conditions.  This suggests 
that LXRα S196A expressing mice have greater CD68+ plaque area under 
normoglycemia due to enhanced monocyte recruitment.  Although LXRα S196A 
expression increased recruitment of monocytes under diabetes, however, it did not alter 
the CD68+ plaque area compared to LXRα WT.  This indicates that LXRα S196A 
expression is affecting another pathway that compensates for increased monocyte 
recruitment.  For example, LXRα S196A expression may inhibit macrophage 
retention/emigration under diabetes. 
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To test whether LXRα S196A expression in macrophages under diabetes affects 
macrophage retention, mice were injected with EdU (5-ethynyl-2'-deoxyuridine) 6 days 
before the end of western diet feeding.  EdU gets incorporated into DNA of proliferating 
progenitor cells, which give rise to circulating Ly6Chi monocytes (Supplemental Figure 
6B).  After 24 hours of EdU injection ~50% of circulating Ly6Chi monocytes were found 
to be labeled with EdU (Supplemental Figure 8B).  We tracked the number of labeled 
cells that infiltrated into the plaques of WT and S196A baseline groups and did not find 
differences between the two groups (Supplemental Figure 8C).  At the time of harvesting 
baseline groups, after 5 days of injection, EdU positive cells were not detected in 
circulation suggesting no new EdU positive cells would enter the plaques after this time 
point (Supplemental Figure 8B).  Therefore, the number of EdU positive cells in the 
plaques after 5 weeks of lipid reduction would reflect macrophages retained in the 
plaque.  We found fewer EdU positive macrophages in regression groups compared to the 
baseline consistent with cells emigrating out of the plaque over time (Figure 4C).  We 
also found that diabetes is associated with increased macrophage retention in mice 
expressing LXRα WT: compared to normoglycemic LXRα WT mice, diabetic LXRα WT 
mice had approximately 50% more macrophages retained in their plaques (Figure 4C).  
Notably, LXRα S196A expression prevented the diabetes-induced increase in 
macrophage retention.  This was independent of macrophage proliferation, since similar 
numbers of cells stained positive for Ki67, a marker of cell proliferation, among the 
regression groups (Supplemental Figure 9).  Thus, LXRα S196A prevents macrophage 
retention in diabetes.  Given that regression of atherosclerosis in Reversa mice has been 
shown to require egress of macrophages from the plaque (21), these findings suggest that 
All rights reserved. No reuse allowed without permission. 
was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint (which. http://dx.doi.org/10.1101/363366doi: bioRxiv preprint first posted online Jul. 6, 2018; 
 13 
LXRα S196A facilitates plaque regression by preventing macrophage accumulation in 
diabetes.  
 
LXRα S196A expressing mice have more circulating monocytes under regression 
conditions 
The increased recruitment of monocytes in the LXRα S196A mice after lipid 
lowering could result from higher numbers of circulating leukocytes (22).  In fact, we 
observed significantly higher levels of circulating monocytes and WBCs in LXRα S196A 
versus LXRα WT expressing mice in regression groups under both normoglycemic and 
diabetic conditions (Figure 5A).  This likely explains the increase in the CD68+ cells in 
normoglycemic LXRα S196A versus LXRα WT-expressing mice during regression.  
This also suggests that LXRα pS196 plays a role in modulating circulating levels of 
WBCs.  
 
LXRα S196A increases CMP proliferation in bone marrow 
Given that LXRα S196A expressing mice have higher monocytes compared to 
LXRα WT under both normoglycemic and diabetic regression conditions, we examined 
whether LXRα S196A affected circulating monocyte levels in the absence of dietary and 
blood glucose modulation.  The monocyte counts in LXRα WT (S196AFL/FL CRE-) and 
LXRα S196A (S196AFL/FL CRE+) mice fed normal chow diet were measured before and 
after tamoxifen administration.  Blood monocytes were monitored over 20 days.  
Induction of LXRα S196A expression led to increased blood monocytes 12 days after the 
first tamoxifen injection (Figure 5B).  In contrast, monocytes were not affected in mice 
All rights reserved. No reuse allowed without permission. 
was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint (which. http://dx.doi.org/10.1101/363366doi: bioRxiv preprint first posted online Jul. 6, 2018; 
 14 
expressing LXRα WT after tamoxifen injection.  At both 12 and 20-days post-tamoxifen 
treatment, mice that expressed LXRα S196A showed significantly higher levels of blood 
monocytes compared to those that expressed LXRα WT.  This suggests that persistent 
LXRα S196A expression in the bone marrow of mice leads to an increase in blood 
monocytes.   
 To examine if hematopoietic progenitor cells were affected by LXRα S196A (23), 
we harvested bone marrow cells from normoglycemic and normolipidemic LXRα WT 
and LXRα S196A mice 20 days after recombination to the S196A allele.  We analyzed 
the proliferation of monocyte progenitors, including hematopoietic stem cells (HSCs), 
common myeloid progenitors (CMPs) and granulocyte-monocyte progenitors (GMPs) by 
flow cytometry, as we have done before (15).  We found that LXRα S196A expression 
increased the proliferation of the CMPs without affecting GMP or HSC populations 
(Figure 5C).  
 
RNA-seq analysis reveals diverse effects of LXRα S196 phosphorylation on gene 
expression of plaque macrophages under normoglycemic and diabetic settings 
To gain insight into the mechanisms of changes in macrophage retention, we 
examined genome-wide expression changes from LXRα S196A and LXRα WT plaque 
macrophages from normoglycemic and diabetic mice by performing RNA sequencing 
from laser-captured CD68+ cells from plaques of regression groups.  Under 
normoglycemic conditions, 447 genes (315 induced and 132 repressed) were modulated 
by LXRα S196A (>1.2 fold change, p<0.01) compared to expression under LXRα WT 
(Figure 6A and Supplementary Figure 10A).  Under diabetic conditions, 212 genes (135 
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induced and 77 repressed) were modulated by LXRα S196A (Figure 6A and 6C).  
Intriguingly, the effects of LXRα S196 phosphorylation were highly dependent on the 
glucose environment because LXRα S196A regulated distinct sets of genes under normal 
and diabetic conditions (Figure 6B).  Moreover, a significant number of genes that were 
upregulated by LXRα S196A under diabetes were downregulated by LXRα S196A under 
normoglycemia and those that were downregulated by LXRα S196A under diabetes were 
upregulated by LXRα S196A in normoglycemia (Table S1).  This suggested that changes 
in glucose levels can switch the propensity of LXRα S196A from being a transcriptional 
activator to a repressor or vice-versa at certain genes.  
Genes upregulated by LXRα S196A under normoglycemia (i.e. repressed by 
LXRα pS196) (Supplementary Figure 10A) belonged to Gene Ontology (GO) classes that 
included cell adhesion, wound healing, cell differentiation and positive regulation of 
apoptotic process (Table 1). Genes downregulated by LXRα S196A (i.e. activated by 
LXRα pS196) aligned to GO classes that contained inflammatory response, chemotaxis, 
response to hypoxia and blood coagulation.  This suggested that LXRα S196A expression 
promoted cell adhesion, and suppressed inflammation under normoglycemia.  Moreover, 
a number of genes involved in positive regulation of apoptosis were upregulated by 
LXRα S196A consistent with increased apoptosis observed in the LXRα S196A plaques 
compared to LXRα WT under normoglycemia (Supplementary Figure 10B). 
We next interrogated genes differentially expressed in LXRα S196A vs. WT 
under diabetic conditions (Figure 6C).  GO classes enriched in genes upregulated by 
LXRα S196A (i.e. repressed by LXRα pS196) include leukocyte migration, chemotaxis, 
immune response and cholesterol homeostasis (Table 2).  In contrast, the genes 
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downregulated by LXRα S196A (i.e. activated by LXRα pS196) were associated with 
cell adhesion, negative regulation of cell migration, negative regulation of TGFβ 
signaling and neutrophil homeostasis (Table 2).  A subset of genes upregulated by LXRα 
S196A have LXR binding sites in their regulatory regions suggesting direct regulation by 
LXRα (25), including CCR6, a chemokine receptor involved in monocyte migration in 
atherosclerosis (26), S100A8 and S100A9, inflammatory proteins secreted at increased 
levels from macrophages from diabetic mice (27).  This suggests that LXRα S196A 
expression reduced plaque macrophage retention in diabetes by enhancing the expression 
of genes in macrophage migration and chemotaxis while repressing genes involved in cell 
adhesion making the macrophages less adhesive to the plaque (Figure 6D and E). 
 
Discussion  
 LXRα is post transcriptionally modified by phosphorylation (11, 26, 27), and yet 
the biological significance of this event is not well understood.  In this study we 
examined the consequence of disrupting LXRα pS196 during regression of 
atherosclerosis in normal and diabetic mice.  We found that diabetic mice expressing 
phosphorylation deficient LXRα S196A displayed reduced macrophage retention in 
plaques, suggesting the non-phosphorylated LXRα at S196 is anti-atherogenic under 
hyperglycemic conditions.  We also found this occurs despite LXRα S196A promotion of 
leukocytosis through stimulation of bone marrow precursor proliferation (Figure 5C), 
which is expected to be pro-atherogenic (Figure 7).  This promotion of leukocytosis was 
counterbalanced by the reduction of macrophage retention such that the plaques in S196A 
mice have similar macrophage content as in WT mice. 
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Phenotypes relevant to atherosclerosis such as plaque size, plaque necrosis and 
apoptosis, macrophage proliferation, plaque collagen content and macrophage 
efferocytosis were unchanged between LXRα WT and S196A groups under the diabetic 
setting.  In contrast, plaque macrophage content, monocyte recruitment, apoptosis and 
necrosis were greater in LXRα S196A as compared to WT group under normoglycemia, 
likely as a result of increased monocytosis in S196A mice.  Under diabetic conditions, 
there too was increased monocyte recruitment; however, this was mitigated by reduced 
macrophage retention in S196A compared to WT.  This led to no change in plaque 
macrophage content between S196A and WT mice in diabetes.  Thus, the 
phosphorylation state of LXRα modulates atherosclerosis regression dependent on 
different glycemic environments, via regulation of macrophage retention and the 
abundance of myeloid precursors. 
Leukocytosis in LXRα S196A mice was unexpected, since there is no literature 
linking LXRα or its phosphorylation status to increased WBCs or monocytes.  It has been 
previously shown that diabetes (19, 28), and reduced expression of the cholesterol 
transporters ABCA1 and ABCG1 in hematopoietic precursors, resulted in leukocytosis 
(29).  We did not see changes in leukocyte numbers, however, as a function of diabetes.  
This might reflect mouse strain or methodological differences between studies.  We also 
did not observe changes in ABCA1 and ABCG1 mRNA expression in plaque 
macrophages in S196A compared to WT mice; however, the regulation of these genes by 
LXRα S196A may differ in hematopoietic progenitor cells.   
LXRα S198 phosphorylation was increased in RAW 264.7 macrophage cells 
expressing human LXRα when cultured in high compared to normal glucose.  LXRα 
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S198 has been reported to be phosphorylated by protein kinase A (PKA) (27) and CK2 
(11), the later which exists as a tetramer with two α catalytic subunits (α and α’), and two 
regulatory b subunits.  We did not see any upregulation in PKA or CK2 subunit mRNA 
expression by RNA-seq in macrophages from regressing plaques in normal versus 
diabetes.  Nor did we see any change in CK2 α or b subunit protein abundance in the 
regressing plaques of normal versus diabetic mice by immunohistochemistry (not 
shown).  This suggests that either there is post-translational activation of PKA or CK2 by 
hyperglycemia or the potential for other glucose sensing mechanisms to increase 
phosphorylation of LXRα, such as either decreased or increased activity of an LXRα 
pS196 phosphatase or kinase. 
Differential gene expression analyses of macrophages (CD68+) in regressing 
plaques from WT versus S196A were consistent with the decreased macrophage retention 
or increased emigration in the plaques of S196A mice: the expression of genes involved 
in cell adhesion were decreased in the S196A compared to WT in diabetes while those in 
macrophage chemotaxis were increased.  Strikingly, there was virtually no overlap in the 
gene expression signatures between WT and S196A plaque macrophages under normal or 
diabetes conditions. This could be due to alterations in LXRα occupancy genome-wide as 
a result of shifts in chromatin accessibility as a function of hyperglycemia.  This could 
also be attributed to differences in the ability of the LXRα to interact with cooperating 
transcription factors under normal versus hyperglycemic conditions that promote receptor 
binding to target genes as a function of LXRα phosphorylation and thereby influence 
global gene expression (30).  Thus, both LXRα phosphorylation and the cellular 
environment appear to play important roles in dictating gene expression in macrophages.  
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Taken together, our data suggest that phosphorylation deficient LXRα reduced the 
retention of macrophages in the plaque, and would therefore be atheroprotective under 
diabetic conditions.  Harnessing the beneficial effects of suppressing LXRα 
phosphorylation systemically, however, would be problematic given the increased 
leukocytosis and enhanced monocyte recruitment to the plaque by the non-
phosphorylated LXRα.  To circumvent this issue, plaque-specific delivery of compounds 
that suppress LXRα phosphorylation or promote the conformation of the non-
phosphorylated receptor might have therapeutic value in promoting the regression of 
atherosclerosis (31).  
 
MATERIALS AND METHODS 
 
Cell culture 
RAW 264.7 cells stably expressing FLAG-tagged human LXRα previously described 
(11) were cultured in Dulbecco's modified Eagle's medium (DMEM, Corning) containing 
10% fetal bovine serum (FBS) and 1 U/mL Penicillin and 1 µg/mL Streptomycin.  Cells 
were routinely tested for mycoplasma and were mycoplasma free. Peritoneal 
macrophages were cultured in DMEM with 10% FBS. Jurkat cells were maintained in 
RPMI medium with 10% FBS with 1 U/mL Penicillin and 1 µg/ml Streptomycin. 
 
Microarray Analysis 
Total RNA was isolated using RNEasy mini kit (Qiagen) and 3 µg of each sample was 
processed for hybridization to the mouse genome 430 2.0 AffyMetrix Expression Array 
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by the Genome Technology Center of NYU Langone School of Medicine. Data are 
representative of four different conditions performed in quadruplicate and were 
normalized using Robust Multichip Average (RMA).  The primary data were analyzed 
for fold-changes of >1.5 between treatment (T+9) and vehicle control cells (DMSO). 
Probesets were analyzed for significance (p < 0.05) using ANOVA.  Genes were 
considered significant if they passed the ANOVA test and displayed a fold-change of 
>1.5 when the values between treated and control samples were compared.  Ingenuity 
Pathway Analysis (IPA) software was used to analyze the gene sets for enriched 
molecular and cellular functions and canonical pathways. 
 
Preparation of whole cell extracts and immunoprecipitation 
Cells were washed twice in PBS and lysed in Triton lysis buffer (50mM HEPES 
pH 7.6, 150mM NaCl, 1mM EDTA pH 8.0, 1mM EGTA pH 8.0, 1mM NaF, 1% Triton 
X-100, 10% glycerol) with protease and phosphatase inhibitor cocktail (Cell Signaling).  
Protein concentrations were measured by using the Bradford assay (Biorad). For 
immunoprecipitation, the lysates were incubated with FLAG antibody conjugated agarose 
beads overnight at 4oC.  The beads were washed once in the lysis buffer and 3 times in 
TBS.  Proteins associated with the antibody were eluted in TBS by competition with 
FLAG peptides. 
 
Western blotting 
Protein samples were mixed with 5x Laemmli sample buffer containing beta-
mercaptoethanol and boiled at 95oC for 5 min to denature the proteins.  Proteins were 
separated on SDS-PAGE polyacrylamide gels and transferred to PVDF membranes 
All rights reserved. No reuse allowed without permission. 
was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint (which. http://dx.doi.org/10.1101/363366doi: bioRxiv preprint first posted online Jul. 6, 2018; 
 21 
(Millipore), incubated with blocking solution (5% BSA in TBS pH 7.4) for 1 h and 
incubated in primary antibody solubilized in blocking solution overnight at 4 °C. 
Antibodies used were anti-LXRα-pS196 (Affinity Purified 1135 (11)) and anti-LXRα 
(Abcam ab41902). Membranes were washed 3 times in TBS with 0.1% Tween (TBST) 
for 10 min and incubated with horseradish peroxidase-conjugated secondary antibody at 
room temperature for 1 h.  Membranes were washed in TBST. The blots were developed 
with ECL detection reagents (E2400, Denville Scientific, Holliston, MA). Quantification 
of Western blots was done by using ImageJ software. 
 
Animals 
Reversa mice (LDLR−/−; ApoB100/100; Mttpfl/fl; Mx1-Cre+/+) (19), global LXRα 
S196A KI mice, WT mice and inducible or non-inducible LXRα S196A phosphorylation 
deficient knock in mice (LXRα S196AFL/FL RosaCreERT2 or LXRα S196AFL/FL obtained 
from Dr. Ines Pineda, University College London, UK) in C57Bl6J background were 
cared for in accordance with the National Institutes of Health guidelines and the NYU 
Institutional Animal Care and Use Committee. Bone marrow from LXRα S196AFL/FL 
or LXRα S196FL/FL RosaCreERT2 mice were transplanted into 12 weeks old Reversa mice 
to generate mice with BM-derived, monocyte-derived cells capable of switching 
expression from LXRα WT to LXRα S196A upon tamoxifen treatment. After 8 weeks of 
BM transplantation, they were placed on Western diet (21% [wt/wt] fat, 0.3% cholesterol 
[Research Diets]) for 16 weeks to allow development of atherosclerotic plaques. At 14.5 
weeks of western diet feeding mice were injected intraperitoneally (IP) daily with 
Tamoxifen (6 mg/40 g, Sigma-Aldrich) for 3 days to switch the expression from LXRα 
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WT to LXRα S196A in LXRα S196FL/FL RosaCreERT2 mice.  After 2 days, mice were 
injected IP with STZ (50 mg/kg, Sigma-Aldrich) or citrate buffer for 5 days to induce 
diabetes mellitus or to serve as a control.  Baseline groups were sacrificed at this time. 
The rest were then switched to a chow diet and were injected 4 times IP with polyinosinic 
polycytidylic RNA (Sigma-Aldrich 15 mg/kg) every other day (13). Regression groups 
were sacrificed after 5 weeks on chow diet. Mice were anesthetized with 
xylazine/ketamine, and blood was collected via cardiac puncture for plasma analyses. 
Mice were perfused with 10% sucrose/saline. Aortic roots were dissected and embedded 
in optimal cutting temperature compound medium (OCT) and frozen immediately and 
stored at –80°C until further use. 
Genotyping primers 
The genotypes of S196AFL/FL, S196AFL/+, S196A+/+  mice were identified by PCR 
using 4 primers: R2: 5′- AAGCATGACCTGCACACAAG -3′; WT: 5′- GGT GTC CCC 
AAG GGT GTC CT -3′; F2: 5′- GGC ATG AGG GAG GAG TGT AA -3′; and SA: 5′- 
GGT GTC CCC AAG GGT GTC CG -3′. Primers R2 and WT identify the wild-type 
allele (642-bp) and FL allele (656-bp). Primers F2 and SA identify the FL allele (411-bp 
fragment). Primer R2 and SA identify mutant allele of LXRα S196A global knock in 
mice (656-bp). To genotype mice for RosaCreERT2 locus, Primers oIMR0092 [Mut], 5′-
AAT CCA TCT TGT TCA ATG GCC GAT C-3′; oIMR3349 [common], 5′-CCA TAT 
GCA TCC CCA GTC TT-3′; and oIMR3350 [WT], 5′-GCG ATG GAT ACA CTC ACT 
GC-3′) were used. Primers oIMR0092 and oIMR3349 detect the mutant allele and 
oIMR3350 and IMR3349 detect the WT allele. 
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Genomic DNA analysis in blood monocytes  
Blood was collected from the mice after 8 weeks of bone marrow transplantation 
and after tamoxifen treatment and from S196AFL/FL, S196AFL/+, S196A+/+ mice as 
controls. Red blood cells were lysed with RBL buffer (Biolegend) and cells were stained 
with PECy7 anti-mouse CD45 and PE anti-mouse CD115 (Biolegend). Blood monocytes 
(CD45hiCD115hi) were sorted by FACS (Beckman Coulter MoFlo). Genomic DNA was 
extracted from the sorted monocytes using the DNEasy blood and tissue kit (Qiagen). 
Relative DNA levels of FL allele were quantified by qPCR using F2-SA primer pair. All 
the values were normalized to relative DNA levels detected using control primer pair. 
Primers used for DNA analysis are control DNA: forward 5’- AGG GAA AGC TCT 
CTG GAG CAT-3’ and reverse: 5’-CAG GAA TTT CTC CAT CCT TTG AGT-3’, F2-
SA: forward 5’-GGC ATG AGG GAG GAG TGT AA-3’ and reverse 5’- GGT GTC 
CCC AAG GGT GTC CG-3’.   
 
Blood glucose and plasma lipoprotein analyses  
Blood samples were centrifuged at 10,000 rpm for 10 minutes and the 
supernatants collected as plasma. Total cholesterol, triglyceride and HDL-C 
concentrations in plasma were measured using colorimetric assays (Wako Diagnostics, 
Richmond, VA). Blood glucose levels were measured with a blood glucometer (Freestyle 
lite, Roche) at the time of harvest.  
 
Histochemical analyses 
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Aortic roots frozen in OCT were serial-sectioned at a thickness of 6 µm onto glass 
slides. For CD68 (macrophage marker) staining, slides were fixed in 100% acetone for 10 
mins and exposed to primary anti-CD68 antibody (Serotec), followed by biotinylated 
secondary antibody (Vector Laboratories), with visualization using a Vectastain ABC kit 
(Vector Laboratories). Sections were counter stained with hematoxylin. To stain for 
LXRα and pS196 in the plaques, sections were fixed in ice-cold acetone for 10 min, 
incubated in 3% H2O2 for 10 min to quench the peroxidase activity. Sections were then 
blocked with 5% normal goat serum (PBS) and stained overnight at 4°C with the primary 
antibody to LXRα (ab3585; Abcam) at 10 µg/ml and LXRα-S196-P (affinity-purified 
rabbit polyclonal 1135 (11)) in 5% normal goat serum–PBS. Sections were incubated 
with a secondary biotinylated anti-rabbit IgG (H+L) antibody (BA-1000; Vector 
Laboratories), followed by horseradish peroxidase streptavidin (SA-5704; Vector 
Laboratories). Staining was visualized using a DAB (3,3′-diaminobenzidine) peroxidase 
substrate kit (SK-4100; Vector Laboratories) following the manufacturer's protocol, and 
the reaction mixture was counterstained with hematoxylin. Microscopic images were 
taken at 10X of aortic root sections and morphometric measurements were performed 
using Image Pro Plus software (Micro Optical Solutions).  
 
Apoptosis analysis 
Apoptosis was analyzed in the aortic roots by staining the plaques with anti-
cleaved caspase 3 (Cell signaling) and counter stained with hematoxylin. Nuclei 
positively stained for the antibody and hematoxylin were considered apoptotic. To 
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quantify apoptosis in the plaque, % plaque cells (nuclei) positive for cleaved caspase 3 
stain was calculated for each mouse.  
 
Proliferation analysis 
Cell proliferation in the plaques were analyzed in aortic roots by staining the 
plaques for Ki67 (abcam). Nuclei positively stained for the antibody and hematoxylin 
were considered proliferating cells. To quantify proliferation in the plaque, the number of 
cells that stained positive for KI67 per section was measured for each mouse.  
 
Necrosis analysis 
Necrosis was quantified in aortic roots by measuring the acellular areas of plaques 
with Image Pro Plus software as previously described (15). 
 
Laser capture microdissection 
6 µm sections of aortic roots were collected on Pen membrane Frame Slides 
(Arcturus). CD68+ cells were isolated from atherosclerotic plaques by laser capture 
microdissection performed under RNase-free conditions (34, 35). Aortic root sections 
were stained with hematoxylin-eosin and cells were captured from approximately 36 
frozen sections. After laser capture microdissection, RNA was isolated using the 
PicoPure Kit (Molecular Devices), and quality and quantity were determined using an 
Agilent 2100 Bioanalyzer (Agilent Technologies).  
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RNA-Seq analysis 
RNASeq libraries were prepared starting from 2.5 ng of total RNA from Baseline 
LXRα WT, LXRα WT Regression Control, LXRα S196A Regression Control, LXRα 
WT Regression STZ, LXRα S196A Regression STZ groups (n=3 or 4) using the 
Clontech SMARTer® Stranded Total RNA-Seq Kit - Pico Input Mammalian, with 5 
cycles of PCR for cDNA amplification and 13 cycles of PCR for library amplification, 
following the manufacturer’s protocol (Cat # 635006). Libraries were purified using 
AMPure beads, quantified by Qubit and QPCR, and visualized in an Agilent Bioanalyzer. 
The libraries were pooled equimolarly, and run on a HiSeq 2500, v4 chemistry, as paired 
end reads, 50 nucleotide in length. Raw sequencing data were received in FASTQ format 
and read mapping was performed using STAR 2.5 against the mm10 reference genome.  
The resulting BAM alignment files were processed using Featurecounts 1.0.5 on its 
respective GRCm38 annotation, obtained from the ENSEMBL database.  Subsequently 
the Bioconductor package DESeq2 (3.4) was used to identify differentially expressed 
genes (DEG).  This package provides statistics for determination of DEG using a model 
based on the negative binomial distribution.  Genes with a p-value < 0.01 were 
determined to be differentially expressed.   
 
Monocyte/Macrophage tracking 
For the egress study, Edu (1 mg/30 g) was injected IP at week 15 before STZ 
treatment to label Ly6Chi monocytes, which can later become Ly6Clo monocytes. For the 
recruitment studies, circulating Ly6Clo monocytes were labeled by injecting mice in the 
retro-orbital vein with 250 µL 1µm Fluoresbrite fluorescein isothiocyanate-dyed (YG) 
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plain microspheres (Polysciences Inc.) diluted in PBS (1:4) 24 hours before harvesting as 
previously described (36, 37). Labeling efficiency was assessed by flow cytometry 24 
hours after injection. For EdU detection, blood samples were collected 24 hours and 5 
days after injecting with EdU. Red blood cells were lysed with RBL buffer (BD 
Biosciences) and cells were stained with APC anti-mouse CD115, PeCy7 anti-mouse 
CD45 and PerCp-Cy5.5 anti-mouse Ly6G/C. EdU positive cells were detected with 
Click-iT® EdU Flow Cytometry Assay Kit (Thermofisher, C10418), following 
manufacturer’s protocol. EdU positive cells in the plaques were detected using Click-iT 
EDU Imaging Kit (MP 10338) following manufacturer’s protocol. For bead detection, 
cells were stained with PECy7 anti-mouse CD45, PE anti-mouse CD115 and APC anti-
mouse Ly6G/C. All antibodies were purchased from Biolegend. Bead labeling in cells 
was detected through FITC channel by flow cytometry and beads were counted in the 
plaques using a fluorescent microscope.  
 
Determining hematological parameters 
Blood was collected before sacrificing the mice by tail bleeding. Total white 
blood cells (WBCs) and monocytes were determined by Genesis Hematology System 
(Oxford Science, Oxford, CT). Total monocytes were also calculated by multiplying total 
WBCs from Hematology system and % monocyte using flow cytometry analysis to 
confirm accuracy. Red blood cells were lysed with RBL buffer (company) and cells were 
stained with PECy7 anti-mouse CD45 and PE anti-mouse CD115 (Biolegend). 
Monocytes were identified by flow cytometry analysis as CD45hiCD115hi cells using a 
LSRII analyzer.   
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Hematopoietic stem and progenitor cells 
Hematopoietic stem and progenitor cell populations were analyzed by flow 
cytometry. Bone marrow from S196FL/FL or S196FL/FL RosaCreERT2 mice were harvested 
20 days after tamoxifen treatment, and red blood cells were lysed with RBL buffer (BD 
Biosciences). Cells were stained with a cocktail of biotinylated antibodies against 
lineage-committed (lin) cells (Gr1, B220, CD11b, CD3, TER119, CD8, CD4) and with 
antibodies for the stem and progenitor cell markers (Sca1, ckit, CD34, CD16/32, Cd150) 
Cells were identified as hematopoietic stem cells (HSCs; lin−, Sac1+, ckit+, CD34-, 
CD150+), common myeloid progenitor (CMP; lin−, Sca1−, ckit+, CD34+, CD16/32mid), 
and granulocyte–macrophage progenitor (GMP; lin−, Sca1−, ckit+, CD34+ and CD16/32hi). 
Cell proliferation in each population was examined using DAPI by determining % cells 
in G2M phase (>2n DNA content). Flow cytometry was performed using an LSRII and all 
flow cytometry data were analyzed using FlowJo X software (Tree Star). 
Efferocytosis Assay 
 
Peritoneal macrophages were isolated from mice by peritoneal lavage 3 days after 
injecting them intraperitoneally with 1 ml of 3% thioglycollate as previously described 
(38) and seeded in plated in a Lab-Tek Chamber Slide system (Thermo Scientific, 
1256518) at a density of 2.5 x 105 per well. Jurkat cells were labeled with Cell Tracker 
Red CMTPX dye (Molecular Probes, C34552) and rendered apoptotic by treating with 
cycloheximide (100 µg/mL) for 6 hrs. Apoptotic Jurkat cells in RPMI with 0.2 % BSA 
were added onto macrophages, at a 5:1 ratio of apoptotic cells: macrophages, and 
incubated for 2 hrs. Media was removed, and cells were washed with ice cold PBS three 
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times to remove non-phagocytized apoptotic cells. Macrophages were fixed by 
incubating in 10% formalin for 10 minutes and washed with PBS three times. 
Macrophages were then stained with Phalloidin Green (Molecular Probes, A12379) and 
slides were mounted with DAPI containing mountant (Molecular probes, P36935). To 
quantify the extent of efferocytosis, macrophages with internalized apoptotic bodies were 
scored and results are expressed as % efferocytosis (number of macrophages with 
engulfed apoptotic cells / total number of macrophages x 100). 
 
Apoptosis Assay 
 
Peritoneal macrophages were seeded in plated in Chamber Slide system as 
mentioned above. Apoptosis was induced by treating cells with LPS (100 µg/mL) and 
cyclohexamide (20 µg/ml) for 4 hrs. Cells were stained with FITC Annexin V and 
Propidium Iodide (BD Biosciences, 556547) for 15 minutes and washed 3 times with the 
binding buffer. Macrophages were fixed by incubating in 10% formalin for 10 minutes 
and washed with PBS three times. Slides were mounted with DAPI containing mountant 
(Molecular probes, P36935). Apoptotic cells (positive for Annexin V and negative for 
Propidium iodide) were scored and results are expressed as % apoptosis. 
 
Statistical analysis 
The values are represented as means ± S.E. All comparisons were made from 
three independent experiments unless otherwise noted for all cell culture experiments. 
Statistical analyses were performed with Prism software (GraphPad Software, Inc., La 
Jolla, CA) using a 1-way ANOVA or a 2-way ANOVA or the two-tailed Student’s t test 
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(*, p ≤ 0.05; **, p ≤ 0.005; ***, p ≤0.0005) as stated. Western blots are representative of 
three independent experiments.  
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FIGURE LEGENDS 
Figure 1. Hyperglycemia influences LXR signaling and enhances LXRα S198 
phosphorylation A) RAW 264.7 macrophages stably expressing human LXRa (RAW- 
LXRa) were cultured under high glucose (25mM D-glucose) or normal glucose (5.5mM 
D-glucose supplemented with L-glucose as an osmotic control).  Macrophages were 
treated with LXR/RXR ligands (5uM T0901317 +1uM 9cisRA) for 4 hours. Total RNA 
was isolated and gene expression was assessed using the Mouse Genome 430 2.0 
AffyMetrix Expression Array. Four independent biological replicates were performed per 
condition. Venn diagram showing overlap between genes affected (induced and repressed 
> 1.5 fold; p < 0.05) by high compared to normal glucose in the absence and presence of 
ligand treatment. The numbers of genes downregulated are shown in red and upregulated 
are shown in blue in high compared to normal glucose. B) Molecular and cellular 
functions of genes regulated by high versus normal glucose under ligand treated 
conditions predicted by IPA. C) RAW-LXRα cells were cultured in normal and high 
glucose, and treated with vehicle control (DMSO), the LXR ligand (5 µM T0901317; T), 
RXR ligand (1 µM 9-cisRA; 9cRA) or the combination of both for 4 h.  LXRα was 
immunoprecipitated with anti-Flag antibody and LXRα protein and S198 phosphorylation 
were detected using an LXRα phospho-S198 and total LXRα antibodies. The Western 
blot was quantitated using ImageJ software, and the ratio of LXRα pS198 to LXRα is 
shown for each sample with DMSO treated sample in normal glucose set to 1. 
 
Figure 2. LXRα S196A expression increases plaque macrophage content in 
normoglycemic mice but not in diabetic mice. A) Experimental design to test the 
All rights reserved. No reuse allowed without permission. 
was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint (which. http://dx.doi.org/10.1101/363366doi: bioRxiv preprint first posted online Jul. 6, 2018; 
 32 
effects of LXRα pS196 in atherosclerosis regression under normoglycemia and diabetes. 
B) Blood glucose levels were measure before harvesting the mice. C) Blood was 
collected from the mice at the time of harvest and total cholesterol was measured by 
using colorimetric assays. D) Aortic roots from baseline and regression groups were 
sectioned, fixed, and stained for CD68 to measure total macrophage content. 
Representative images of CD68 immunostaining are shown for each group (left panel). 
The percent area occupied by CD68+ cells of the plaque area was quantified using Image 
Pro Plus Software.  Data (mean ± SEM) (n≥8) were analyzed using one-way ANOVA 
followed by Tukey’s multiple comparison test. P < 0.05 values were considered to be 
significant, *P < 0.05, **P < 0.005, ***P < 0.0005 and ****P < 0.00005. WT; 
S196AFL/FL CRE– recipient Reversa mice; SA: S196AFL/FL CRE+ recipient Reversa mice. 
 
Figure 3. LXRα S196A expression increases plaque necrotic area and apoptosis in 
normoglycemic mice but not in diabetic mice.  The percent necrotic area of plaques 
from the regression groups are shown. Data (mean ± SEM; n≥6) were analyzed using 
one-way ANOVA followed by Tukey’s multiple comparison test. P < 0.05 values were 
considered to be significant, *P < 0.05, **P < 0.005 and ***P < 0.005.  B) Aortic roots 
from the regression groups were stained for cleaved caspase 3 to detect cells undergoing 
apoptosis. The number of apoptotic cells per section were counted and precent apoptotic 
cells in the plaque are shown. Data (mean ± SEM; n≥7) were analyzed as above. C) 
Apoptotic Jurkat cells were added to peritoneal macrophages that express LXRα WT or 
LXRα S196A cultured under normal and high glucose conditions, and efferocytosis was 
quantified and expressed as the percent of cells having ingested apoptotic cells. D) 
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Peritoneal macrophages expressing LXRα WT or LXRα S196A under normal glucose 
and high glucose were treated with LPS and cyclohexamide to induce apoptosis for 4 
hours and % apoptosis was measured. The experiments in C and D were performed three 
times with similar results. Each experiment was performed in triplicate, and 
representative experiments are shown. The error bars represent SEM. Significance was 
determined as above;. *P < 0.05. 
 
Figure 4. LXRα S196A expression and diabetes influence monocyte/macrophage 
trafficking in the plaque. A) Reversa mice were injected with EdU 6 days before the 
end of western diet feeding to measure macrophage retention in the plaque and with 
fluorescent latex beads 24 h before sacrificing the mice to assess monocyte recruitment. 
B) To measure monocyte recruitment, beads were counted in the aortic root using 
fluorescent microscopy. C) To assess macrophage retention the number of EdU positive 
cells were counted in aortic root from the regression groups.  Data are expressed as mean 
± SEM (n≥6 in each group). Data were analyzed using one-way ANOVA followed by 
Tukey’s multiple comparison test. P < 0.05 values were considered to be significant, *P < 
0.05, **P < 0.005 and ***P < 0.005.  
 
Figure 5. LXRα S196A expressing mice have more circulating monocytes and 
increased CMP proliferation during regression. A) Quantification of circulating 
monocytes and WBCs in mice. Data are expressed as mean ± SEM (n≥8 per group). Data 
were analyzed using one-way ANOVA followed by Tukey’s multiple comparison test. P 
< 0.05 values were considered to be significant, *P < 0.05, **P < 0.005 and ***P < 
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0.005. B) S196AFL/FLCre- (WT) and S196AFL/FLCre+ (S196A) mice were treated with 
tamoxifen on Day 0. Blood monocytes were measured on Day 0, 7, 12 and 20 as 
percentage of WBCs was determined using Genesis Hematology system. C) 
Hematopoetic stem and progenitor cell populations in the bone marrow in G2M phase 
(cells with >2n DNA content) was measured by flow cytometry suing DAPI. CMP; 
common myeloid progenitor; GMP, granulocyte-macrophage progenitor; and HSC, 
hematopoetic stem cell.  
 
Figure 6. RNA-seq analysis reveals distinct set of genes regulated by LXRα S196A 
in plaque macrophages under normoglycemia and diabetes. A) Bar diagram showing 
the number of genes that exhibited >1.2-fold expression changes (p<0.01) (induced and 
repressed) from LXRα S196A under normoglycemia and diabetes. B) Venn diagrams 
showing overlap between genes regulated by LXRα S196A under normoglycemia and 
diabetes in plaque macrophages: induced genes are shown on the top panel and repressed 
genes on the bottom. C) Heatmap showing genes differentially expressed in LXRα 
S196A vs. WT groups under diabetic condition (P-value <0.01). D) Genes upregulated 
(>1.2 fold, # P-value <0.01, ^ P-value <0.001) by LXRα S196A under diabetic condition 
that are involved in cell migration and chemotaxis E) Genes downregulated (>1.2 fold, # 
P-value <0.01, ^ P-value <0.001) by LXRα S196A under diabetic condition that are 
involved in cell adhesion. 
 
Figure 7.  Effects of LXRα S196A expression under normoglycemia and diabetes in 
atherosclerosis regression.  Under normoglycemic condition, LXRα S196A expression 
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increases proliferating CMPs in the bone marrow that leads to increased circulating 
leukocytes.  This increased monocyte infiltration, apoptosis and necrosis in the plaques 
leading to impaired regression under normoglycemia. Interestingly, LXRα S196A 
expression in diabetic mice leads to reduced macrophage retention and reverses 
macrophage accumulation in the plaque.  This is through increased expression of genes 
promoting chemotaxis and migration, and decreased expression of genes involved with 
cell adhesion.  This effect of LXRα S196A is anti-atherogenic.  Therefore, despite the 
damaging effects of leukocytosis, LXRα S196A does not change plaque macrophage 
content and does not impair regression under diabetes compared to LXRα WT. 
 
Table 1. Gene Ontology analysis of genes upregulated or downregulated by LXRα 
S196A vs. LXRα WT expressing plaque macrophages under normoglycemia. Fold 
enrichment of actual over expected probesets along with the P-values are displayed for 
each biological process. 
 
Table 2. Gene Ontology analysis of genes upregulated or downregulated by LXRα 
S196A vs. LXRα WT expressing plaque macrophages under diabetes. Fold enrichment of 
actual over expected probesets along with the P-values are displayed for each biological 
process. 
 
Supplemental Figure 1. Signaling pathways affected by hyperglycemia in 
macrophages. A) RAW 264.7 macrophages stably expressing human LXRa (RAW- 
LXRa) were cultured under high glucose (25mM D-glucose) or normal glucose (5.5mM 
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D-glucose supplemented with L-glucose as an osmotic control) treated with vehicle 
(DMSO) or LXR ligands (5uM T0901317 +1uM 9cisRA) for 4 hours. Gene expression 
was assessed using the Mouse Genome 430 2.0 AffyMetrix Expression Array. B) Genes 
regulated by high versus normal glucose under ligand treated conditions were subjected 
to canonical signaling pathway analysis using IPA. Select signaling pathways predicted 
by IPA are shown. 
 
Supplemental Figure 2. Inducible phosphorylation deficient LXRα S196A knock in 
mouse genetics. A) S196AFL/FL mice are homozygous for Floxed (FL) allele which 
contains LXRα WT exon 5 (Ex5) and LXRα S196A exon 5 (Ex5’) of LXRα gene in 
opposite orientation flanked by lox sites sensitive to CRE recombinase. The mice express 
LXRα WT but can switch to LXRα S196A expression in the presence of CRE 
recombinase.  We bred these mice to the Rosa26CreERT2 line that express CRE fused to 
Estrogen Receptor (ER) ligand binding domain in all cell types to obtain S196AFL/FL 
RosaCreERT2 mice (homozygous for FL allele and heterozygote for Cre expressing 
allele). Administration of tamoxifen in these mice mediate recombination at lox sites 
resulting in the replacement of Ex5 with Ex5’. This allows Ex5’ to be in the proper 
orientation for expression, thereby switching expression from LXRα WT to LXRα 
S196A. B) DNA and amino acid sequences in LXRα WT (Ex5) and S196A (Ex5’) 
highlighting the serine to alanine mutation at amino acid 196.  
 
Supplemental Figure 3. Quantification of bone marrow reconstitution and 
tamoxifen induced CRE-mediated recombination efficiency A) Schematic of a primer 
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pair F2-SA that selectively amplifies FL allele in S196AFL/FL mice. B) Blood monocytes 
were sorted by flow cytometry from S196AFL/FL S196AFL/+ and S196A+/+ mice and total 
genomic DNA extracted. Relative FL DNA levels in S196AFL/FL (arbitrarily set to 1), 
S196AFL/+ and S196A+/+ (WT homozygote) mice quantified by qPCR using F2-SA primer 
pair. C) Quantification of FL DNA levels in mice after BM transplant to monitor relative 
amount of BM donor derived FL DNA in Reversa mice receiving either S196AFL/FL Cre- 
or S196AFL/FL Cre+ BM (D) Quantification of FL DNA levels in mice after tamoxifen 
injections in S196AFL/FLCre+ recipients to assess the CRE-mediated recombination 
efficiency. 
 
Supplemental Figure 4. LXRα pS196 abundance is reduced in plaques of S196A 
FL/FL Cre+ BM recipient compared to S196A FL/FL Cre- mice. Aortic roots from the 
normoglycemic mice in the regression groups that were S196A FL/FL Cre+ or S196A FL/FL 
Cre- BM recipients were sectioned, fixed, and stained for LXRα pS196. Representative 
images of LXRα pS196 immunostaining are shown for each regression group.  
 
Supplemental Figure 5. Plaque total LXRα abundance is not altered by diabetes and 
S196A mutation. Aortic roots from the mice in the regression groups were sectioned, 
fixed, and stained for LXRα. Representative images of LXRα immunostaining are shown 
for each regression group.  
 
Supplemental Figure 6. Triglyceride and HDLC levels. A-B) Blood was collected 
from the mice at the time of harvest and plasma triglycerides (A) and HDLC (B) were 
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measured by using colorimetric assays. Data (mean ± SEM) (n≥8) were analyzed using 
one-way ANOVA followed by Tukey’s multiple comparison test. P < 0.05 values were 
considered to be significant, *P < 0.05, **P < 0.005, ***P < 0.0005 and ****P < 
0.00005. WT; S196AFL/FL Cre– recipient Reversa mice; SA: S196AFL/FL Cre+ recipient 
Reversa mice 
 
Supplemental Figure 7. Total plaque area is not affected by LXRα S196A 
expression. The total area of the plaques was quantified using Image Pro Plus Software.  
Data (mean ± SEM) (n≥8) were analyzed using one-way ANOVA followed by Tukey’s 
multiple comparison test. P < 0.05 values were considered to be significant, *P < 0.05, 
**P < 0.005, ***P < 0.0005 and ****P < 0.00005. WT; S196AFL/FL Cre– recipient 
Reversa mice; SA: S196AFL/FL Cre+ recipient Reversa mice. 
 
 
Supplemental Figure 8. Fluorescent bead labeling and EdU incorporation in 
circulating cells were efficient and uniform across regression groups. A) Reversa 
mice were injected with fluorescent latex beads 24 h before sacrifice to harvest aortic 
roots. Blood was collected prior to the harvest from the tail vein and precent circulating 
Ly6Clo monocytes containing beads (FITC+) were measured by flow cytometry. B) 
Reversa mice were injected with EdU 6 days before the end of western diet feeding. To 
test the efficiency of EdU incorporation, blood was collected from LXRα WT and LXRα 
S196A expressing groups 24 h and 5 days after injecting EdU and percent EdU positive 
Ly6Chi monocytes in circulation was measured by flow cytometry in both S196AFL/FL 
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RosaCreERT2 (WT) and S196AFL/FL (S196A) recipient Reversa mice. C) The number of 
EdU positive cells was counted in aortic root plaques from the baseline groups.  Data are 
expressed as mean ± SEM (n≥6 in each group). Data are expressed as mean ± SEM (n≥6 
in each group).  Data were analyzed using one-way ANOVA followed by Tukey’s 
multiple comparison test. P < 0.05 values were considered to be significant, *P < 0.05, 
**P < 0.005 and ***P < 0.005.  
 
Supplemental Figure 9. LXRα S196A expression and diabetes do not alter plaque 
cell proliferation. Aortic roots from the regression groups were sectioned, fixed, and 
stained for Ki67 to detect cells undergoing proliferation. The number of Ki67 cells per 
section was counted and are displayed in the graph. Data (mean ± SEM; n≥6) were 
analyzed using one-way ANOVA followed by Tukey’s multiple comparison test. P < 
0.05 values were considered to be significant, *P < 0.05, **P < 0.005 and ***P < 0.005. 
 
Supplemental Figure 10. Genes regulated by LXRα S196A under normoglycemic 
conditions A) Heatmap showing genes differentially expressed in LXRα S196A vs. WT 
groups under normoglycemic condition (P-value <0.01).  B) Genes upregulated (>1.2 
fold, # P-value <0.01, ^ P-value <0.001) by LXRα S196A under normoglycemic 
condition that are involved in positive regulation of apoptosis. 
 
Supplementary Table 1. Select genes regulated differently by LXRα S196A under 
normoglycemic and diabetic conditions (>1.2 fold, p<0.01). Fold-change compared to 
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their LXRα WT counterpart under the given glucose setting are displayed with respective 
P-values.  
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Biological Process 
Number of 
genes P-Value 
Fold 
Enrichment 
Upregulated in S196A vs. WT- Normoglycemia 
cell adhesion 33 2.04 x 10-12 4.52 
collagen fibril organization 8 1.60 x 10-06 13.64 
extracellular matrix organization 10 5.49 x 10-05 5.83 
negative regulation of cell migration 9 1.95 x 10-04 5.64 
wound healing 8 5.30 x 10-04 5.66 
cell differentiation 23 3.48 x 10-03 1.96 
positive regulation of TGFB receptor 
signaling pathway 4 5.34 x 10-03 11.08 
positive regulation of macrophage 
chemotaxis 3 2.34 x 10-02 12.46 
positive regulation of apoptotic process 11 3.02 x 10-02 2.18 
 
Downregulated in S196A vs. WT- Normoglycemia 
inflammatory response 16 3.38 x 10-09 7.44 
chemotaxis 8 8.67 x 10-06 10.85 
cellular response to tumor necrosis factor 7 6.27 x 10-05 10.18 
response to hypoxia 7 1.25 x 10-03 5.83 
blood coagulation 5 1.84 x 10-03 9.52 
regulation of cell shape 5 1.10 x 10-02 5.76 
Biological Process 
Number of 
genes P-Value 
Fold  
Enrichment 
 
Upregulated in S196A vs. WT-Diabetes 
leukocyte migration involved in inflammatory 
response 6 5.11 x 10-08 53.84 
chemotaxis 8 6.78 x10-05 7.91 
immune system process 12 4.49 x 10-04 3.66 
inflammatory response 11 7.44 x 10-04 3.73 
positive regulation of positive chemotaxis 3 4.50 x 10-03 29.16 
cellular response to interleukin-1 5 4.85 x 10-03 7.29 
cholesterol homeostasis 4 1.66 x 10-02 7.41 
response to hypoxia 6 2.44 x 10-02 3.65 
positive regulation of cell migration 6 3.00 x 10-02 3.45 
 
Downregulated in S196A vs. WT-Diabetes 
negative regulation of TGFB receptor signaling  5 4.10 x 10-04 14.19 
cell adhesion 11 1.21 x 10-03 3.48 
negative regulation of sequence-specific DNA  
binding transcription factor activity 4 1.01 x 10-02 8.88 
positive regulation of cell-substrate adhesion 3 3.02 x 10-02 10.95 
negative regulation of cell migration 4 3.15 x 10-02 5.78 
positive regulation of transcription 9 3.35 x 10-02 2.39 
neutrophil homeostasis 2 4.44 x 10-02 43.78 
